GLP-1 Savings Cards and Copay Assistance in the US

A savings card is help with a price, a coverage decision

The phrase pay as little as $25 describes the lowest payment available under an offer. It does not mean every eligible person pays $25. The manufacturer contribution has a ceiling, so a person with a $300 copay and a $100 card limit could still owe about $200.<br/><br/>High-deductible plans can make the first fills of a plan year particularly expensive. Until the deductible is met, the plan may leave the person paying much of its negotiated price. A card may lower the pharmacy amount, yet it can reach its annual limit long before December.<br/><br/>Ask the plan whether it uses a copay accumulator or copay maximizer. An accumulator may stop manufacturer assistance from counting toward a deductible or annual out-of-pocket maximum. A maximizer may set cost sharing around available manufacturer help. Novo Nordisk says people in some accumulator-adjustment or maximizer programs may be unable to continue its diabetes savings offer, and Lilly terms also exclude some alternate funding programs.

Cash-pay offers follow different rules

Cash pay is not the same as copay assistance. A self-pay offer is generally processed outside insurance, so it may lower the purchase price while providing no deductible or out-of-pocket credit. Novo Nordisk's Ozempic terms state that self-pay purchases cannot be applied to insurance deductibles or out-of-pocket maximums.<br/><br/>For Zepbound, Lilly's current offers distinguish between the single-dose pen and the single-patient-use KwikPen. The device, dose, coverage status and refill timing can change the available offer. Check the exact product on the prescription rather than assuming a brand-level price applies.<br/><br/>A cash route can be useful for a particular fill, but it may be a poor fit if meeting a deductible would soon lower insured costs. Ask the pharmacy to process the insurance claim first, then compare the final insured amount with the current self-pay terms.

Government coverage has a separate route

Manufacturer copay cards for Wegovy, Ozempic, Zepbound and Mounjaro generally exclude Medicare, Medicaid, Veterans Affairs, Department of Defense and TRICARE beneficiaries. Paying cash for one fill does not usually make a person with government-funded coverage eligible for a commercial card.<br/><br/>On July 1, 2026, the Centers for Medicare & Medicaid Services, or CMS, began the Medicare GLP-1 Bridge. CMS states that certain eligible Medicare Part D beneficiaries can access specified GLP-1 medicines for $50 per month. Eligibility depends on clinical criteria and plan circumstances, so it is not automatic and is not interchangeable with a manufacturer coupon.

Employer coverage remains uneven

KFF found that 19% of firms with 200 or more workers covered GLP-1 medicines primarily for weight loss in 2025. The figure was 16% for firms with 200 to 999 workers, 30% for those with 1,000 to 4,999 workers, and 43% for firms with 5,000 or more workers.<br/><br/>Those figures describe firms' largest plans, not the percentage of all covered workers. They still explain a common experience: two people with job-based coverage may receive very different answers for the same prescription. An employer's formulary, exclusions and prior-authorization rules matter more than the presence of an insurance card.

Affordability is also a maintenance question

Savings offers can make starting possible, but the cost question often extends beyond the first few months. In the STEP 1 semaglutide extension, participants had lost an average of 17.3% of starting body weight after 68 weeks of semaglutide 2.4 mg. One year after treatment and lifestyle support stopped, they had regained 11.6 percentage points, about two-thirds of their prior loss, leaving an average net loss of 5.6% from baseline.<br/><br/>In SURMOUNT-4, participants lost an average of 20.9% during a 36-week tirzepatide lead-in. During the following 52 weeks, people switched to placebo regained 14.0% from randomization, while those who continued tirzepatide lost another 5.5% on average.<br/><br/>These are structured-trial group averages, not a forecast for one person. They do show why it is reasonable to ask about a maintenance plan before depending on a limited card, a temporary self-pay offer, or coverage that may change at the next plan year.

Safety and pharmacy questions still matter

Cost does not replace a safety review. FDA labels for Wegovy and Zepbound carry a boxed warning about thyroid C-cell tumors and list contraindications for people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. The labels also describe risks including pancreatitis, gallbladder problems, dehydration-related kidney injury, severe gastrointestinal reactions, and low blood sugar when used with certain diabetes medicines.<br/><br/>A clinician or pharmacist can help connect these label warnings to your health history and other medicines. They can also clarify whether the prescribed brand is being used for an FDA-approved indication, what documents a plan may require, and what symptoms should prompt contact with the care team.

Prepare before the next fill

Keep a short refill record with the medicine name, device, prescribed use, remaining deductible, pharmacy quote, insurer payment, and final amount after assistance. It gives you a clearer view of whether the offer is lowering the amount and whether you are nearing an annual cap.<br/><br/>Save the insurer's written decision. Note whether it was approved, denied, pending prior authorization, or subject to step therapy. Ask whether manufacturer support counts toward the deductible and annual out-of-pocket maximum, and confirm the offer expiration date before each fill.<br/><br/>Useful questions include: Is this brand prescribed for an FDA-approved use? What documentation will the plan need? Does assistance count toward my deductible? What will I pay if the savings offer ends? If I have Medicare, do I meet the separate Medicare GLP-1 Bridge criteria?